Anacetrapib: Difference between revisions
imported>David E. Volk mNo edit summary |
imported>David E. Volk (chemistry and mechanism of action) |
||
| Line 19: | Line 19: | ||
Anacetrapib is related to [[torcetrapib]].<ref name="pmid21082868">{{cite journal| author=Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM et al.| title=Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. | journal=N Engl J Med | year= 2010 | volume= | issue= | pages= | pmid=21082868 | doi=10.1056/NEJMoa1009744 | pmc= | url= }} </ref> | Anacetrapib is related to [[torcetrapib]].<ref name="pmid21082868">{{cite journal| author=Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM et al.| title=Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. | journal=N Engl J Med | year= 2010 | volume= | issue= | pages= | pmid=21082868 | doi=10.1056/NEJMoa1009744 | pmc= | url= }} </ref> | ||
== Chemistry and Mechanism of Action == | |||
The chemical name of anacetrapib, distributed by Merck, is 2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one. It has a formula weight of 637.51 g/mol and its CAS registration number is 875446-37-0. Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP), a key protein involved in reverse cholesterol transport, and its use increases high-density lipoprotein [[cholesterol]] ([[HDC]]). Other CETP inhibitors include [[dalcetrapib]] and [[torcetrapib]]. <ref name="20406242">{{cite journal| author=Gurfinkel, R., Joy, T.R.| title=Anacetrapib: Hope for CETP Inhibitors | journal=Cardiovasc. Ther. | year= 2010 | volume= | issue= | pages= | pmid=21082868 | doi= | pmc= | url= http://www.ncbi.nlm.nih.gov/pubmed/20406242 }} </ref>,<ref name="19705341 ">{{cite journal| author=Mason, D. | title=Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclrerosis | journal=Curr Opin Investig Drugs | year= 2009 | volume= 10 | issue= 9 | pages= 980-987 | pmid=19705341 | doi= | pmc= | url= http://www.ncbi.nlm.nih.gov/pubmed/20406242 }} </ref>, | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 09:29, 26 November 2010
|
| |||||||
| anacetrapib | |||||||
| |||||||
| Uses: | cholesterol regulation | ||||||
| Properties: | see below | ||||||
| Hazards: | see below | ||||||
| |||||||
In health care, anacetrapib (anacet'rapib) is an oxazolidinone medication that is a cholesteryl ester transfer protein inhibitor that raises HDL cholesterol and reduces LDL cholesterol.[1]
Anacetrapib is related to torcetrapib.[2]
Chemistry and Mechanism of Action
The chemical name of anacetrapib, distributed by Merck, is 2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one. It has a formula weight of 637.51 g/mol and its CAS registration number is 875446-37-0. Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP), a key protein involved in reverse cholesterol transport, and its use increases high-density lipoprotein cholesterol (HDC). Other CETP inhibitors include dalcetrapib and torcetrapib. Cite error: Invalid <ref> tag; name cannot be a simple integer. Use a descriptive title,Cite error: Invalid <ref> tag; name cannot be a simple integer. Use a descriptive title,
References
- ↑ Anonymous (2024), Anacetrapib (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM et al. (2010). "Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.". N Engl J Med. DOI:10.1056/NEJMoa1009744. PMID 21082868. Research Blogging.